Research progress on the mechanism and effect of Sodium Zirconium Cy-closilicate combined with renin-angiotensin-aldosterone system inhibitors in treatment of chronic kidney disease
Renin-angiotensin-aldosterone system inhibitors(RAASi)can delay the progression of chronic kidney disease(CKD),but are often limited by their susceptibility to hyperkalemia.A new oral potassium binder,Sodium Zirconium Cyclosilicate(SZC),combined with RAASi,can rapidly reduce the serum potassium level and improve kidney function in CKD patients.However,the action mechanism of the combined treatment of CKD has not been fully elucidated.Therefore,this paper mainly discusses the mechanism and therapeutic effect of SZC and RAASi on CKD when used alone or in combination,aiming to provide a more optimized treatment plan for patients with CKD.
Sodium Zirconium CyclosilicateRenin-angiotensin-aldosterone system inhibitorsChronic kidney diseaseHyperkalemia
NETL
NSTL
万方数据
